
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Supplements and Featured Publications
about 24 years ago
Participating Facultyabout 24 years ago
Cardiorenal Differences Among NSAIDs and Coxibs: Real-World Experience




